首页> 外文期刊>Bioorganic and medicinal chemistry >Development, validation and pilot screening of an in vitro multi-cellular three-dimensional cancer spheroid assay for anti-cancer drug testing
【24h】

Development, validation and pilot screening of an in vitro multi-cellular three-dimensional cancer spheroid assay for anti-cancer drug testing

机译:用于抗癌药物测试的体外多细胞三维癌症球体测定方法的开发,验证和初步筛选

获取原文
获取原文并翻译 | 示例
           

摘要

It has been demonstrated that two-dimensional (2D) monolayer cancer cell proliferation assay for anti-cancer drug screening is a very artificial model and cannot represent the characteristics of three-dimensional (3D) solid tumors. The multi-cellular in vitro 3D tumor spheroid model is of intermediate complexity, and can provide a bridge to the gap between the complex in vivo tumors and simple in vitro monolayer cell cultures. In this study, a simple and cost-effective cancer 3D spheroid assay suitable for small molecule anti-cancer compound screening was developed, standardized and validated on H292 non-small lung cancer cell line. A pilot screening with this assay was performed utilizing a compound library consisting of 41 anti-cancer agents. The traditional 2D monolayer cell proliferation assay was also performed with the same cell line and compounds. A correlational study based on the IC50 values from the 2D and 3D assays was conducted. There is low correlation with the two sets of biological data, suggesting the two screening methods provide different information regarding the potency of the tested drug candidates.
机译:已经证明用于抗癌药物筛选的二维(2D)单层癌细胞增殖测定是一种非常人为的模型,不能代表三维(3D)实体瘤的特征。多细胞体外3D肿瘤球体模型具有中等复杂性,可以为复杂的体内肿瘤与简单的体外单层细胞培养之间的桥梁提供桥梁。在这项研究中,开发了一种适用于小分子抗癌化合物筛选的简单且经济高效的癌症3D球体测定法,并在H292非小细胞肺癌细胞系上进行了标准化和验证。使用由41种抗癌药组成的化合物文库进行该试验的初步筛选。还使用相同的细胞系和化合物进行了传统的2D单层细胞增殖测定。进行了基于2D和3D分析的IC50值的相关研究。与两组生物学数据之间的相关性较低,表明这两种筛选方法提供了有关待测药物潜力的不同信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号